BACKGROUND Mucormycosis, a fungal infection caused by Rhizopus species is on the rise in COVID-19 patients as a result of their suppressed immunity. The current therapies include systemic administration of Amphotericin B. HYPOTHESIS AND METHOD We screened several triazole broad-spectrum antifungal agents against the therapeutic target in mucormycosis using computational techniques like molecular docking and compared them with isavuconazole, an approved drug. RESULT The study concluded that 4 triazole drugs, pramiconazole, itraconazole, posaconazole and ketoconazole were strong candidates to be further evaluated and developed as a treatment for mucormycosis. CONCLUSION Novel topical and oral therapies could be developed from these drug leads.
Drug repurposing of triazoles against mucormycosis using molecular docking: A short communication.